Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
LRMR - Larimar Therapeutics, Inc.
Market Cap 156.63M P/E - EPS this Y -69.00% Ern Qtrly Grth -
Income -58.34M Forward P/E -3.42 EPS next Y -40.10% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 1.47 EPS next 5Y - 52W High Chg -47.00%
Recommedations 1.40 Quick Ratio 10.72 Shares Outstanding 63.81M 52W Low Chg 137.00%
Insider Own 1.45% ROA -23.59% Shares Float 31.93M Beta 0.77
Inst Own 108.07% ROE -37.48% Shares Shorted/Prior 3.33M/3.63M Price 3.62
Gross Margin - Profit Margin - Avg. Volume 363,732 Target Price 22.14
Oper. Margin - Earnings Date Nov 12 Volume 214,145 Change -11.06%
Healthcare | Biotechnology | United States
About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc. News
12/17/24 Larimar Therapeutics announces initial data from OLE study of nomlabofusp
12/16/24 Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
11/18/24 Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
10/30/24 Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
10/17/24 Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
09/19/24 Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
08/27/24 Larimar Therapeutics to Participate in Upcoming Investor Conferences
08/07/24 Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
07/30/24 Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
05/30/24 Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
05/20/24 Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
05/09/24 Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
03/14/24 Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
03/14/24 Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
03/11/24 Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
03/06/24 Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
02/16/24 Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
02/14/24 Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
02/13/24 Larimar Therapeutics Announces Proposed Underwritten Public Offering
02/12/24 Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Celano Michael Chief Financial Offi.. Chief Financial Officer May 17 Buy 3.7263 5,000 18,632 112,746 05/18/23
BEN-MAIMON CAROLE President and CEO President and CEO May 17 Buy 3.705 5,000 18,525 266,829 05/18/23
Truitt Joseph Director Director May 17 Buy 3.73 2,750 10,258 2,750 05/18/23
Flynn James E - - Sep 16 Buy 3.15 11,111,108 34,999,990 2,777,777 09/20/22
Hamilton Thomas Edward Director Director Sep 16 Buy 3.15 317,460 999,999 507,590 09/20/22
Celano Michael Chief Financial Offi.. Chief Financial Officer Sep 16 Buy 3.15 31,746 100,000 31,746 09/19/22
BEN-MAIMON CAROLE President and CEO President and CEO Sep 16 Buy 3.15 31,746 100,000 56,829 09/19/22